Supplementary Fig.S1 from Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E-based Antibody-Drug Conjugate for treatment of Nectin-4-expressing Cancers | Synapse
September 16, 2024
Supplementary Fig.S1 from Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E-based Antibody-Drug Conjugate for treatment of Nectin-4-expressing Cancers
Puntos clave
Los puntos clave no están disponibles para este artículo en este momento.
Resumen
Structure of linker-payload complexes and conjugation process of 9MW2821.